Skin Conditions & Dermatology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

This Phase 3 study evaluated rocatinlimab, a new targeted treatment for adults with moderate-to-severe atopic dermatitis, a condition that causes intense itching and skin inflammation. The results from many sites worldwide show promise for this monoclonal antibody to reduce symptoms and improve daily comfort. If approved, rocatinlimab could give patients a new option beyond current therapies.

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

This ongoing study in Singapore is testing a digital app designed to help people with eczema, psoriasis, and urticaria manage their symptoms through psychological support. The app aims to lower the overall burden of these chronic skin conditions without relying on medication, potentially improving quality of life. The trial is recruiting now and will follow participants over 32 weeks.

Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program

This trial in Singapore focuses on teaching individuals, especially those with darker skin tones, how to recognize signs of skin cancer early through a self-detection program. Early detection is key to better outcomes, and this program could empower people at risk to catch skin cancer sooner. The study is currently enrolling 280 participants to test the program’s impact.

Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents

This study in the United States is exploring a digital program that encourages sun safety habits among teenagers and their parents. By using mobile and social media tools, the intervention aims to reduce skin cancer risk through better sun protection behaviors. The trial is recruiting families interested in learning how to stay safe in the sun.

AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images

In Turkey, this study is testing an artificial intelligence tool that analyzes skin images to classify the risk and predict subtypes of basal cell carcinoma, the most common type of skin cancer. If successful, this AI approach could help doctors make quicker and more accurate diagnoses, leading to better treatment decisions. The trial is currently recruiting patients with confirmed basal cell carcinoma.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.